Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

HARVARD BIOSCIENCE INC Director's Dealing 2017

May 30, 2017

34975_dirs_2017-05-30_5152fc36-b335-4178-b8dc-3e63357e7802.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2017-05-25

Reporting Person: Gagnon Robert E. (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-05-25 Common Stock A 108696 $0.00 Acquired 365377 Direct
2017-05-25 Common Stock A 108696 $0.00 Acquired 474073 Direct
2017-05-26 Common Stock P 1000 $2.33 Acquired 475073 Direct

Footnotes

F1: Represents a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019.

F2: Includes (a) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (b) a deferred stock award of 88,652 restricted stock units which shall vest in full on May 6, 2018; (c) a deferred stock award of 66,489 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (d) a deferred stock award of 13,250 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (e) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (f) 60,173 shares of common stock held by the Reporting Person.

F3: Represents a deferred stock award of 108,696 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021.

F4: Includes (a) a deferred stock award of 108,696 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (c) a deferred stock award of 88,652 restricted stock units which shall vest in full on May 6, 2018; (d) a deferred stock award of 66,489 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 13,250 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (f) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 60,173 shares of common stock held by the Reporting Person.

F5: This transaction was executed in multiple trades at prices ranging from $2.33 to $2.34. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F6: Includes (a) a deferred stock award of 108,696 restricted stock units which shall vest in four equal installments on January 1, 2018, 2019, 2020 and 2021; (b) a deferred stock award of 108,696 restricted stock units which shall vest in full on May 25, 2019; (c) a deferred stock award of 88,652 restricted stock units which shall vest in full on May 6, 2018; (d) a deferred stock award of 66,489 restricted stock units which shall vest in three equal installments on January 1, 2018, 2019 and 2020; (e) a deferred stock award of 13,250 restricted stock units which shall vest in two equal installments on January 1, 2018 and 2019; (f) a deferred stock award of 28,117 restricted stock units with performance based vesting conditions, which shall vest on August 3, 2018 contingent upon achievement of a performance condition tied to relative total shareholder return; and (g) 61,173 shares of common stock held by the Reporting Person.